The discovery of genetic mutations as the underlying cause of ARVD/C was an important breakthrough The clinical criteria currently used 2 are based on family history, the presence of structural ...

The first-line therapy for arrhythmogenic right ventricular cardiomyopathy (ARVC) is considered to be β-blockers, which are generally well tolerated. However, findings from the Multidisciplinary ...